Largest Clinical Trials companies in Netherlands by Market Capitalization

This ranking features the largest 8 Clinical Trials companies in Netherlands ranked by Market Capitalization, totaling a Market Capitalization of USD 19.49 B, for July 05, 2025.

#	Name	Share Price Year-To-Date (YTD) return Price to Earnings Ratio (P/E) Revenue Revenue Year-on-Year (YoY) growth Operating Income EBIT EBITDA Free Cash Flow Dividend Yield Free Cash Flow Yield Total Assets Total Liabilities Cash and Short-Term Investments	Stock Price	Change	Price (30 days)	52W low/high	Sector

Items per page

Frequently Asked Questions

Which Clinical Trials company in Netherlands has the highest Market Capitalization ?

The Clinical Trials company in Netherlands with the highest Market Capitalization is Qiagen N.V. (NYSE: QGEN) at USD 10.47 B.

Which Clinical Trials company in Netherlands has the lowest Market Capitalization ?

The Clinical Trials company in Netherlands with the lowest Market Capitalization is LAVA Therapeutics N.V. (NasdaqGS: LVTX) at USD 34.72 M.

What are the top 10 Clinical Trials companies in Netherlands by Market Capitalization ?

The top 10 Clinical Trials companies in Netherlands by Market Capitalization are Qiagen N.V., Merus N.V., NewAmsterdam Pharma Company N.V., Pharvaris N.V., uniQure N.V., Pharming Group N.V., ProQR Therapeutics N.V. and LAVA Therapeutics N.V..

What are the bottom 10 Clinical Trials companies in Netherlands by Market Capitalization ?

The bottom 10 Clinical Trials companies in Netherlands by Market Capitalization are LAVA Therapeutics N.V., ProQR Therapeutics N.V., Pharming Group N.V., uniQure N.V., Pharvaris N.V., NewAmsterdam Pharma Company N.V., Merus N.V. and Qiagen N.V..